Biogen inks $1B RayThera buyout to bag preclinical immunology assets Read more →
F2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test Read more →
‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game Read more →
